Kura Oncology (NASDAQ:KURA) Lowered to Neutral Rating by BTIG Research

Kura Oncology (NASDAQ:KURA) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a report issued on Thursday,Briefing.com Automated Import reports.

Several other brokerages have also issued reports on KURA. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. Scotiabank dropped their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.75.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $9.05 on Thursday. The stock has a market cap of $703.73 million, a P/E ratio of -3.83 and a beta of 0.78. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $8.83 and its two-hundred day moving average price is $15.16. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the previous year, the company earned ($0.50) earnings per share. As a group, equities analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,255 shares of company stock valued at $100,739 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

A number of hedge funds have recently bought and sold shares of KURA. nVerses Capital LLC purchased a new stake in Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology in the third quarter worth approximately $146,000. Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the third quarter worth $215,000. Bellevue Group AG lifted its stake in shares of Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Kura Oncology in the 3rd quarter worth $268,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.